Why REGENXBIO Inc.’s (RGNX) Stock Is Up 5.15%
As of Friday, November 06, REGENXBIO Inc.’s RGNX share price has surged by 5.15%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why REGENXBIO Inc.’s (RGNX) Stock Is Up 5.38%
As of Tuesday, November 03, REGENXBIO Inc.’s RGNX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Tudor Pop
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 5.16%
As of Friday, October 23, REGENXBIO Inc.’s RGNX share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Michael Rose
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 6.20%
As of Wednesday, October 14, REGENXBIO Inc.’s RGNX share price has dipped by 6.20%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 6.44%
As of Tuesday, October 13, REGENXBIO Inc.’s RGNX share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $503.9 | $219.9 | 38% |
|
| Shares Out (Mil) | 65.3 | 54.1 | 54% |
|
| Institutional Ownership | 89.7% | 92.9% | 58% |
|
| Float (Mil) | 57.2 | 41.4 | 49% |
|
| Beta | 1.23 | 0.95 | 72% |
|
| Avg Daily Volume (000s) | 1,252 | 522 | 72% |
|
| Price Change (52-week) |
(34.4%) | 44.7% | 27% |
|
| Growth | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.0% | 13.2% | 24% |
|
| Net Income (5yr) | (11.7%) | (10.1%) | 28% |
|
| EPS (5yr) | (4.7%) | 15.8% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (15.7%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.980) | ($3.460) | ($2.945) | |
| Month Ago EPS | ($0.982) | ($3.492) | ($2.975) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.845) | ($3.456) | ($2.314) | |
| Year/Year Chg | 57.1% | (8.0%) | (52.6%) | |
| Financials | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $154 | $38 | 30% |
|
| Net Income (TTM) (Mil) | ($175) | ($44) | 7% |
|
| EPS (TTM) | ($3.152) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($152) | ($35) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $37 | $0 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $234 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | $488 | $166 | 34% |
|
| Valuation | RGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.40 | 2.06 | 72% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (64.5%) | 67.3% | 2% |
|
| Net Margin | (113.9%) | (61.0%) | 7% |
|
| ROA | (35.4%) | (47.5%) | 15% |
|
| ROE | (113.2%) | (52.7%) | 8% |
|
| Liabilities to Assets | 68.2% | 29.6% | 64% |
|
| F-Score | 3 | 3 | 18% |
|
REGENXBIO Inc. did not pass any screens on 11/6/2026.
